Stoke Therapeutics, Inc. (STOK), on Monday, announced that it has appointed Ian Smith as Chief Executive Officer.
Smith has served as Interim CEO since March 2025. Smith will continue to serve as a Director on the Company's Board of Directors.
Arthur Tzianabos will resume his role as Chairman of the Board after serving as Executive Chairman.
Smith was selected after conducting a comprehensive search. It became clear that Ian is uniquely qualified to lead Stoke and deeply committed to our science, our mission, and our people.
A global Phase 3 trial of Stoke Therapeutics' lead candidate, zorevunersen, is currently in progress. The therapy is a first-in-class, potentially disease-modifying treatment for Dravet syndrome, a severe developmental and epileptic encephalopathy marked by recurrent seizures and notable cognitive and behavioral challenges.
Stoke Therapeutics closed trading 2.98% higher ta $25.56 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.